885 related articles for article (PubMed ID: 10495069)
1. Antiplatelet agents in the prevention of cardiovascular morbidity and mortality in older patients with vascular disease.
Aronow WS
Drugs Aging; 1999 Aug; 15(2):91-101. PubMed ID: 10495069
[TBL] [Abstract][Full Text] [Related]
2. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
3. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
4. Oral antiplatelet therapy in cerebrovascular disease, coronary artery disease, and peripheral arterial disease.
Tran H; Anand SS
JAMA; 2004 Oct; 292(15):1867-74. PubMed ID: 15494585
[TBL] [Abstract][Full Text] [Related]
5. Evidence with antiplatelet therapy and ADP-receptor antagonists.
Easton JD
Cerebrovasc Dis; 2003; 16 Suppl 1():20-6. PubMed ID: 12698015
[TBL] [Abstract][Full Text] [Related]
6. Antiplatelet therapy in the treatment of atherothrombotic disease: considering the evidence.
Aronow WS
Geriatrics; 2007 Apr; 62(4):12-24. PubMed ID: 17408314
[TBL] [Abstract][Full Text] [Related]
7. From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients.
Hacke W
Cerebrovasc Dis; 2002; 13 Suppl 1():22-6. PubMed ID: 11803184
[TBL] [Abstract][Full Text] [Related]
8. Clopidogrel: a review of its use in the prevention of atherothrombosis.
Jarvis B; Simpson K
Drugs; 2000 Aug; 60(2):347-77. PubMed ID: 10983738
[TBL] [Abstract][Full Text] [Related]
9. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Antithrombotic Trialists' Collaboration
BMJ; 2002 Jan; 324(7329):71-86. PubMed ID: 11786451
[TBL] [Abstract][Full Text] [Related]
10. Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
Hankey GJ; Sudlow CL; Dunbabin DW
Cochrane Database Syst Rev; 2000; (2):CD001246. PubMed ID: 10796426
[TBL] [Abstract][Full Text] [Related]
11. Role of antiplatelet drugs in the prevention of cardiovascular events.
Tendera M; Wojakowski W
Thromb Res; 2003 Jun; 110(5-6):355-9. PubMed ID: 14592562
[TBL] [Abstract][Full Text] [Related]
12. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
13. Update on aspirin in the treatment and prevention of cardiovascular disease.
Hennekens CH
Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
[TBL] [Abstract][Full Text] [Related]
14. Management of atherothrombosis with clopidogrel in high-risk patients with recent transient ischaemic attack or ischaemic stroke (MATCH): study design and baseline data.
Diener HC; Bogousslavsky J; Brass LM; Cimminiello C; Csiba L; Kaste M; Leys D; Matias-Guiu J; Rupprecht HJ
Cerebrovasc Dis; 2004; 17(2-3):253-61. PubMed ID: 14981346
[TBL] [Abstract][Full Text] [Related]
15. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Hankey GJ
Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events.
Squizzato A; Bellesini M; Takeda A; Middeldorp S; Donadini MP
Cochrane Database Syst Rev; 2017 Dec; 12(12):CD005158. PubMed ID: 29240976
[TBL] [Abstract][Full Text] [Related]
17. Value of antiplatelet therapy in preventing thrombotic events in generalized vascular disease.
Montalescot G
Clin Cardiol; 2000 Nov; 23 Suppl 6(Suppl 6):VI-18-22. PubMed ID: 11129682
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
19. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
20. Antiplatelet therapy in the prevention of ischaemic stroke.
Verry M; Panak E; Cazenave JP
Nouv Rev Fr Hematol (1978); 1994 Jun; 36(3):213-28. PubMed ID: 7971242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
